Costs were calculated using cost function figures compared with usual costs. 5 key findings →
Design: randomized controlled trial Participants: 847 Evidence: high
Full summary, score breakdown and related studies → Original source
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
No change was found in the Qualidem total score (range: 0-111) over 2 years. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
After cohort matching, 48% of participants were women (n = 74 464), 61% were white (n = 93 442), and 31% (n = 48 056) were Medicare Advantage insured, with a mean (SD) age of 64 (10) years. 5 key findings →
Design: cohort study Participants: 154 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This was a retrospective cohort study to examine differences in health service utilization and outcomes between FFS and MA patients in SNFs following hip fracture hospitalization during the period January 1, 2011, to June 30, 2015, and followed up until December 31, 2015. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Forty-three percent of the residents were not able to perform the balance test in SPPB. 5 key findings →
Participants: 696 Evidence: low
Full summary, score breakdown and related studies → Original source
We found that a larger share of Hispanic Medicare residents that are admitted to nursing homes have ADRD compared with African American and White beneficiaries. 3 key findings →
Participants: 1,302,099 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
On Census Day, 1.4% of the study sample were living in a nursing home, 1.2% in a seniors' residence, 7.1% in a private dwelling with additional family, and 90.3% in a private dwelling. 5 key findings →
Participants: 81,411 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A total of 2,098 MAPD patients meeting study inclusion/exclusion criteria and with a PA for alirocumab were identified between March 1, 2016 and February 28, 2017. 5 key findings →
Participants: 1,730 Evidence: moderate
Full summary, score breakdown and related studies → Original source
As full citizens, people with dementia are entitled to engage in social and occupational activities in residential care settings. 1 key finding →
Participants: 73 Evidence: low
Full summary, score breakdown and related studies → Original source
Of 15,390 narratives collected from 3139 patients with PsA for exploratory analysis, physical concepts were the most common (81.5%), followed by emotional (50.7%), cognitive (20.0%), role activity (8.1%), and social (5.6%) concepts. 5 key findings →
Participants: 3,139 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
44/100
Greater spend on social care (including availability of care home places) was associated with reduced spend in health care, with shorter length of hospital stay and decrease in readmissions. 2 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
For patients with serious comorbidities, diabetes management guidelines recommend more relaxed glycemic targets (glycosylated hemoglobin [HbA1c] <8-8.5% rather than <7%) and cautious use of agents known to cause hypoglycemia. 5 key findings →
Participants: 216,839 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Stress is critically involved in the development and progression of disease. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Observational and audit data were collected for 181 patients (average age = 82.5 years) across the two hospitals. 5 key findings →
Participants: 181 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
AimTo explore the experiences and challenges for residential care home staff when managing the healthcare needs of their residents, in particular those living with dementia. 1 key finding →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source
Diabetes care guidelines recommend more relaxed glycemic targets for patients with specific chronic conditions because they are thought to have an increased risk of hypoglycemia, limited life expectancy, and/or high clinical complexity. 3 key findings →
Participants: 216,839 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Nonpharmacological practices to address BPSDs include sensory practices (aromatherapy, massage, multi-sensory stimulation, bright light therapy), psychosocial practices (validation therapy, reminiscence therapy, music therapy, pet therapy, meaningful activities), and structured care protocols (bathing, mouth care). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The annual number of deaths at hospital was consistently increased over time from 1996 to 2016 (age-adjusted OR: 6.01; 95% CI 5.81 to 6.21 versus home deaths). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our robust machine learning based analytical pipeline consists of segmentation, radiomic texture extraction, feature normalization and selection, and predictive-model generation. 5 key findings →
Participants: 40 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Serious concerns over the rising cost of cancer drugs in the United States1-3 are increasing,4-9 following a decade during which prices rose from an average of less than $10 000/year to more than $170 000/year in 2017.10 Despite the drug industry's wish to be “part of the solution,” the problem continues to worsen.6 Between 1995 and 2013, the launch price of cancer drugs increased by 10%-12% every year.11 According to a March 2018 report, the Average Wholesale Prices of drugs increased at unprecedented rates.12 A study by Gordon and colleagues showed a 25% average annual price increase of drugs already on the market, despite competition.13 Cancer drugs spending doubled since 2013 and is expected to double again by 2022.14 This suggests that health care is different from other industries where traditional free market forces are effective in lowering prices, and that other measures are needed. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The everyday landscape of occupational therapy (OT) in oncology is underexplored, hindering targeted improvements. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Some of the considerations that need to be taken into account in coming to a decision include: Disease prevalence and burden in the country The existing health-care model and system The ratio of health-care providers to patient Cost and health-care funding in the country The current and projected health-care demand and needs The perception of the population on FP s and primary care providers versus that of specialists in hospitals and The networks and strengths of the primary care model in the country. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A growing population of individuals with multimorbidity, cognitive impairment and functional decline live in the community but are homebound, defined as rarely or never leaving home. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →